ACVRL1
Activin receptor type-1-like
As of the edition of 20 October 2026, ACVRL1 (activin receptor type-1-like, UniProt P37023) has 2 drugs tested at it and 3 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P37023
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 7
- Disease areas
- Cancer; Digestive system; Bones, joints and muscles; Inherited and neonatal; Lungs and airways; Pregnancy and women's health; Urinary and reproductive
- Registered trials of its drugs
- 10
Drugs at this target
| Status | Count |
|---|---|
| Stopped | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Ascrinvacumab | Stopped | Phase 2 | none listed |
| Panulisib | Stopped | Phase 1 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Undetermined | 1 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| Pfizer | Route A |
| Piramal Enterprises | Route A |
The other 1 company at ACVRL1
In the product3 companies in all; 1 is not named here, and no score is.
See the 3 companies at ACVRL1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.